AMGN Amgen
Solid cash machine on a patent treadmill; the price already assumes 9% growth that patent expiries make unlikely.
The business
Amgen discovers, makes, and sells biologic and small-molecule drugs for bone health (Prolia/Xgeva, Evenity), cardiovascular (Repatha), inflammation (Enbrel, Otezla, Tezspire, and Horizon's rare-disease portfolio including Tepezza and Krystexxa), and oncology (Blincyto, Imdelltra). It earns high margins on patent-protected drugs and is building a biosimilars business. Patent expiries constantly wear down revenue, so the company has to keep replacing it through R&D and acquisitions.
Quality gate · 77/100
Moat & management
| Moat | narrow moat |
| Source | intangible |
| Trajectory | stable |
| Management | adequate |
Patents and complex biologics manufacturing protect individual products, but each patent expires. Biosimilars are now eroding Prolia/Xgeva and Enbrel faces its own patent cliff, so the moat depends on the pipeline continually refilling it. The scale in biologics manufacturing and commercialization is real but not unique to Amgen.
Management has a record of disciplined dividends and opportunistic buybacks, but the roughly $28B Horizon acquisition pushed net debt to about 2.6x EBITDA, and buybacks have been paused to pay it down. They have executed well on deleveraging, but their late-stage pipeline bets (MariTide) carry binary risk.
Owner-earnings inputs
| Owner earnings (TTM) | 10.18B |
| Owner-earnings yield | 4.5% |
| Free-cash-flow yield | 4.5% |
| Growth used (normalized) | 5.0% |
| Market-implied growth (reverse DCF) | 9.2% |
| Terminal growth | 3.0% |
| Discount rate (hurdle) | 9.0% |
Projected owner earnings
| Yr | Owner earnings | Growth | PV |
|---|---|---|---|
| 1 | 10.68B | 5.0% | 9.80B |
| 2 | 11.19B | 4.8% | 9.42B |
| 3 | 11.70B | 4.6% | 9.04B |
| 4 | 12.21B | 4.3% | 8.65B |
| 5 | 12.71B | 4.1% | 8.26B |
| 6 | 13.21B | 3.9% | 7.88B |
| 7 | 13.69B | 3.7% | 7.49B |
| 8 | 14.16B | 3.4% | 7.11B |
| 9 | 14.62B | 3.2% | 6.73B |
| 10 | 15.06B | 3.0% | 6.36B |
Key risks
- Prolia/Xgeva biosimilar erosion and the late-decade Enbrel loss of exclusivity
- MariTide failing to compete with Lilly/Novo in obesity, or the obesity market becoming commoditized on price
- IRA Medicare price negotiation and US drug-pricing pressure (most-favored-nation policy, tariffs) compressing margins
Catalysts
- MariTide Phase 3 data and an obesity launch
- Growth from Repatha, Evenity, Tezspire and Imdelltra plus debt paydown leading to renewed buybacks
⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · Price pays for ~9%/yr owner-earnings growth over 10y (reverse DCF); model credits 5%. · Rich vs our conservative value, but a quality business is not a short — stance is WAIT for a better price, not sell.